Data Sheet (Cat.No.T6710)

TargetMol

Troxipide

Chemical Properties



CAS No. : 30751-05-4

Formula: C15H22N2O4

Molecular Weight: 294.35

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Troxipide (Aplace), a new-type systemic non-antisecretory gastric cytoprotective agent, which is mucus-secreting, anti-ulcer, and anti-inflammatory properties irrespective of pH of stomach or duodenum.
Targets(IC50)	Others
In vitro	Troxipide is a new-type anti-ulcer compound that has an inhibitory effect on human neutrophil migration and has various agonist-induced activation. It inhibits neutrophil-mediated inflammation and oxidative stress but does not improve gastric mucus composition and output. In addition, it can increase the secretion of the prostaglandin, a cytoprotective agent.
In vivo	Gastric mucosal metabolism and blood flow will be enhanced by Troxipide.
Kinase Assay	Surface Plasmon Resonance (SPR) studies: The binding experiments are carried out on a ProteOn XPR36 biosensor at 25°C using the HTE sensor chip. The flow cells of the sensor chip are loaded with a nickel solution at 30 μL/min for 120 s to saturate the Tris-NTA surface with Ni(II) ions. Purified His-tagged STAT3 and STAT5 in PBST buffer (PBS with 0.005% (v/v) Tween-20 and 0.001% DMSO pH 7.4) is injected in the first and second channels of the chip respectively in the vertical direction at a flow rate of 25 μg/μL for 300 s, which attained, on average, ~8000 resonance unit (RU). After a wash with PBST buffer, inhibitors binding to the immobilized proteins is monitored by injecting a range of concentrations along with a blank at a flow rate of 100 μL/min for 200 s for each of these small molecules. When the injection of the small molecule inhibitor is completed, running buffer is allowed to flow over the immobilized substrates for the non-specifically bound inhibitors to dissociate for 600 s. Following dissociation of the inhibitors, the chip surface is regenerated with an injection of 1 M NaCl at a flow rate of 100 μL/ml for 18 s. Interspot channel reference is used for non-specific binding corrections and the blank channel used with each analyte injection served as a double reference to correct for possible baseline drift. Data are analyzed using ProteOn Manager Software version 3.1. The Langmuir 1:1 binding model was used to determine the KD values.

Solubility Information

Solubility	DMSO: 7.5 mg/mL (25.48 mM),Sonication is recommended. Ethanol: 3 mg/mL (10.19 mM),Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.3973 mL	16.9866 mL	33.9732 mL
5 mM	0.6795 mL	3.3973 mL	6.7946 mL
10 mM	0.3397 mL	1.6987 mL	3.3973 mL
50 mM	0.0679 mL	0.3397 mL	0.6795 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Kusugami K, et al. Dig Liver Dis, 2000, 32(4), 305-311.
Dewan B, et al. Gastroenterol Res Pract, 2010; 2010: 758397.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481